Regional Immune-Related Gene Determination: Principles, Methods, and Clinical Applications

Regional immune-related gene determination is a molecular diagnostic assay that quantifies the expression of immune-related genes within precisely defined histological regions of a tissue specimen, such as the tumor core, invasive margin, and adjacent stroma. By resolving spatial differences in immune gene activity, this test delivers a high-resolution portrait of the local immune microenvironment to support immunotherapy decision-making, translational research, and biomarker development. This article outlines the technical principles, sample requirements, testing items, analytical methods, quality standards, and practical applications of regional immune-related gene determination.

Technical Overview

Regional immune-related gene determination (RIRGD) is a spatially resolved molecular testing approach that measures the expression levels of immune-associated genes in anatomically or histologically defined regions of a specimen. Unlike bulk gene expression profiling, which averages signals across an entire tissue sample, regional determination preserves the spatial context of immune activity, allowing direct comparison of the tumor core, invasive front, peritumoral stroma, and adjacent normal tissue.

The biological rationale for regional analysis stems from the marked spatial heterogeneity of the tumor immune microenvironment (TIME). Cytotoxic T-cell infiltration, interferon signaling, antigen presentation capacity, and immune checkpoint expression frequently differ between the tumor center and the invasive margin. Because these regional differences strongly influence response to immune checkpoint inhibitors and other immunotherapies, region-specific gene expression data often provide predictive information that bulk analysis cannot capture.

A typical regional immune-related gene determination workflow integrates pathology annotation, region-of-interest isolation, targeted RNA quantification, and bioinformatic signature scoring, performed under the quality frameworks of ISO 15189 medical laboratory accreditation and, where applicable, ISO/IEC 17025 requirements for testing laboratories.

• Spatially resolved quantification of immune gene expression across defined tissue regions
• Comprehensive coverage of checkpoints, T-cell effectors, antigen presentation, cytokine signaling, and immunosuppressive mediators
• Compatible with routine formalin-fixed paraffin-embedded (FFPE) archival specimens
• Region-to-region comparative analysis with standardized signature scoring
• Support for immunotherapy stratification, clinical trial enrollment, and translational research

Testing Samples

FFPE Tissue Sections

Formalin-fixed paraffin-embedded tissue is the most commonly accepted sample type, as it is the standard preparation in surgical pathology and permits retrospective analysis of archival material. Sections of 5 to 10 micrometers on glass slides are required, accompanied by a hematoxylin-and-eosin (H&E) stained section for region annotation. Specimens should contain sufficient viable tumor or target tissue in each region of interest, typically with adequate nucleated cell density and acceptable RNA integrity as assessed by internal reference genes.

Fresh-Frozen Tissue

Fresh or flash-frozen tissue specimens generally yield the highest-quality RNA and are preferred when spatial transcriptomic platforms with high gene-panel density are used. Frozen specimens should be embedded in optimal cutting temperature medium, sectioned under RNase-free conditions, and transported on dry ice to preserve transcript integrity.

Biopsy and Small Specimens

Core needle biopsies and endoscopic biopsies can be analyzed when they contain distinguishable regions such as tumor epithelium and adjacent desmoplastic stroma. Because tissue quantity is limited, panel configurations and minimum cellularity thresholds are adjusted according to validated assay specifications for low-input specimens.

Sample Requirements and Pre-Analytical Considerations

Pre-analytical variables including fixation time, decalcification, and storage duration influence RNA quality and are controlled in accordance with recognized pre-analytical specifications for FFPE molecular testing. General acceptance criteria include:

• Adequate tissue area and cellularity in each annotated region of interest
• Tumor or target cell content confirmed by a qualified pathologist
• Acceptable amplification of housekeeping control genes
• Complete clinical and pathological context including diagnosis, anatomical site, and prior therapy
• Proper chain-of-custody documentation and traceable specimen identification

Testing Items

Regional immune-related gene determination panels are designed to interrogate the principal functional axes of the immune response within each selected region. Representative gene categories and markers are summarized below; specific panel content may be tailored to the disease context and study objectives.

Immune Checkpoint Genes

• CD274 (PD-L1) and PDCD1LG2 (PD-L2) for inhibitory ligand expression
• PDCD1 (PD-1) for exhausted or activated T-cell presence
• CTLA4, LAG3, HAVCR2 (TIM-3), and TIGIT for additional inhibitory receptors
• IDO1 and VTCN1 (B7-H4) for metabolic and adaptive immune resistance mediators

T-Cell Activation and Cytotoxic Effector Genes

• CD3D, CD3E, and CD3G for total T-cell abundance
• CD8A and CD8B for cytotoxic T-lineage representation
• GZMA, GZMB, GZMK, and PRF1 for cytolytic granule activity
• IFNG and CXCR3-associated activation markers for effector function

Antigen Processing and Presentation Genes

• HLA-A, HLA-B, and HLA-C for class I presentation machinery integrity
• B2M, TAP1, TAP2, and TAPBP for antigen processing competence
• CIITA, HLA-DRA, and HLA-DRB1 for class II-mediated presentation
• PSMB8 and PSMB9 for immunoproteasome activity

Cytokine, Chemokine, and Interferon Signaling Genes

• CXCL9, CXCL10, and CCL5 for T-cell recruiting chemokines
• IFNG and its downstream interferon-gamma signature genes
• STAT1, IRF1, ISG15, IFIT1, and MX1 for interferon pathway activation
• TGFB1 and IL10-associated signaling for regulatory cytokine tone

Immunosuppressive and Myeloid Marker Genes

• FOXP3 for regulatory T-cell representation
• CD163, MRC1 (CD206), and CSF1R for tumor-associated macrophage polarization
• CEACAM8 and CXCL8-associated markers for neutrophilic infiltration
• POSTN, FAP, and ACTA2 for cancer-associated fibroblast and stromal exclusion

Composite Regional Signatures

• Regional cytotoxic T-cell score derived from effector gene modules
• Interferon-gamma signaling activation index per region
• Antigen presentation competence score
• Immune-inflamed, immune-excluded, and immune-desert classification
• Invasive margin versus tumor core immune gradient metrics

Testing Methods

Pathologist Annotation and Region-of-Interest Definition

Testing begins with microscopic review of the H&E-stained reference section by a qualified pathologist, who delineates the regions to be analyzed, such as tumor core, invasive margin, stromal compartment, and adjacent normal tissue. Digital pathology imaging may be used to document and register region boundaries, ensuring that molecular results are unambiguously linked to their anatomical origin.

Laser Capture Microdissection Followed by RNA Quantification

Laser capture microdissection (LCM) enables physical isolation of annotated regions from tissue sections under direct microscopic visualization. RNA extracted from each dissected region is then quantified using reverse transcription quantitative PCR (RT-qPCR) or droplet digital PCR following MIQE-conforming assay design, providing sensitive, target-by-target expression measurement with region-level resolution.

Multiplexed Digital Gene Expression Counting

Digital multiplexed counting platforms allow direct quantification of hundreds of immune-related transcripts from limited FFPE-derived RNA without amplification bias. Hybridization-based capture with barcoded reporter chemistry supports robust multi-gene panel analysis, and results can be normalized across regions to construct standardized immune signatures.

Single-Molecule and Multiplex RNA In Situ Hybridization

RNA in situ hybridization (RNA-ISH) detects individual transcript molecules directly within intact tissue architecture using punctate probe visualization. Quantified signal dots per cell, or per unit area, provide single-cell and sub-regional resolution for selected targets, making RNA-ISH particularly valuable for validating regional gradients identified by panel-based methods.

Spatial Transcriptomic Profiling

Array-based spatial transcriptomics captures genome-scale or targeted transcript expression across ordered positional barcodes applied to a tissue section, enabling unbiased mapping of immune gene activity. Region masks derived from histological annotation are projected onto the spatial data, generating region-specific expression matrices and immune microenvironment maps.

Targeted RNA Sequencing

Targeted RNA sequencing using anchored multiplex or amplicon-based enrichment offers scalable gene coverage with strong analytical sensitivity in degraded FFPE RNA. Sequencing libraries from microdissected or macrodissected regions are analyzed through validated bioinformatic pipelines covering alignment, quantification, fusion and variant filtering where applicable, and region-wise differential expression statistics.

Bioinformatic Analysis and Reporting

All raw data undergo quality control, normalization against stable housekeeping genes, and signature-level computation. Reported elements typically include per-region expression values, region-to-region fold changes, composite immune scores, immune phenotype classification, and interpretive commentary prepared within the clinical or research context. Statistical comparisons between regions are performed with pre-specified methods, and reports clearly state assay limitations and RNA quality indicators.

Quality Assurance and Method Validation

Assays are validated for analytical sensitivity, specificity, precision, linearity, and reportable range before clinical deployment, following applicable requirements of ISO 15189 and relevant CLSI molecular testing guidelines. Participation in external quality assessment schemes, routine use of positive and negative controls, and documented competency of technical personnel are integral components of the quality system in accredited third-party laboratories.

Applications

Immune Microenvironment Phenotyping

Regional gene expression data classify specimens into immune-inflamed, immune-excluded, and immune-desert phenotypes and reveal whether immunosuppressive programs are concentrated at the invasive front, within the tumor parenchyma, or in the stromal compartment. This phenotyping informs mechanisms of immune evasion, such as loss of antigen presentation or chemokine-mediated T-cell exclusion.

Immunotherapy Response Prediction

Pre-existing T-cell-inflamed gene expression signatures, interferon-gamma pathway activation, and checkpoint gene co-expression within tumor regions are established correlates of response to immune checkpoint inhibitors. Regional determination refines these predictions by confirming whether effector signatures are spatially engaged with tumor cells rather than confined to peritumoral compartments.

Clinical Trial Stratification and Biomarker Development

Pharmaceutical sponsors and investigators use regional immune gene profiles as enrollment biomarkers and pharmacodynamic endpoints. Serial biopsies analyzed before and after treatment enable quantitative monitoring of pharmacodynamic immune modulation, on-treatment pathway engagement, and adaptive resistance development in defined tissue compartments.

Prognostic Assessment

In multiple tumor types, the density and activation state of immune infiltration measured at the invasive margin carry independent prognostic value. Regional gene expression scoring operationalizes these observations into reproducible molecular metrics applicable to prognosis evaluation and disease monitoring research.

Translational and Mechanistic Research

Academic and industry laboratories apply regional determination to study immune heterogeneity across metastatic sites, clonal evolution of immune escape, the impact of radiotherapy or chemotherapy on local immunity, and the design of region-targeted therapeutic strategies including intratumoral delivery approaches.

FAQ

What types of specimens can be tested?

Routine FFPE tissue sections, fresh-frozen tissue, and selected biopsy specimens are acceptable, provided each annotated region contains sufficient cells and adequate RNA quality as demonstrated by housekeeping gene performance.

How are the analyzed regions defined?

Regions are delineated by a qualified pathologist on an H&E-stained reference section, typically including the tumor core, invasive margin, peritumoral stroma, and adjacent normal tissue, and the same regions are traced onto unstained sections used for molecular analysis.

How long does testing take?

Typical turnaround ranges from seven to fifteen working days depending on the platform, panel size, and whether microdissection or spatial profiling is required; complex retrospective studies may require longer analysis periods.

What results are provided in the report?

Reports include per-region expression values for all assayed genes, region-to-region comparisons, composite immune signature scores, immune phenotype classification, RNA quality metrics, and interpretive commentary contextualized to the clinical or research question.

Can archived FFPE blocks from several years ago be used?

Archival FFPE material can frequently be analyzed successfully, although RNA fragmentation increases with storage age and harsh fixation. Acceptance is determined case by case through RNA quality assessment using validated control targets.

How is assay quality ensured?

Testing is performed in ISO 15189-accredited medical laboratories or ISO/IEC 17025-accredited third-party laboratories, with documented method validation, calibrator and control materials, external quality assessment participation, and supervised bioinformatic pipelines.

Is regional determination different from bulk gene expression profiling?

Yes. Bulk profiling averages signals across all compartments, whereas regional determination resolves expression differences between anatomically defined areas, revealing spatial patterns such as margin-restricted immune activation that bulk methods cannot detect.